View in Other Languages

Regeneus Ltd

ASX:RGS ISIN:AU000000RGS6

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

       

Latest Headlines

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔1/30/2019 3:51:34 PM

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) New CEO Appointed to Accelerate Global Growth

🕔1/23/2019 9:48:46 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.

Read Full Article

Regeneus Ltd (ASX:RGS) Chinese Patent Granted for Biomarkers for Stem Cell Therapy

🕔12/3/2018 9:34:26 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders

🕔11/22/2018 2:06:22 PM

Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018

🕔10/31/2018 4:26:22 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

🕔10/24/2018 9:08:53 AM

Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent Office Issues Notice of Intention to Grant European Patent

🕔10/18/2018 9:11:57 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

🕔9/6/2018 9:18:09 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

🕔8/30/2018 2:32:07 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2018

🕔8/30/2018 2:13:22 PM

Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Cancer Vaccine

🕔7/30/2018 9:45:25 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability. The study known as the ACTIVATE trial, is the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results

🕔7/25/2018 10:00:00 AM

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Office to Allow Key Patent for Progenza

🕔7/10/2018 9:01:37 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for issuance of a patent covering the composition and use of Progenza.

Read Full Article

Regeneus Ltd (ASX:RGS) Update on Licensing Progenza in Japan

🕔7/3/2018 10:00:36 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it was on track to complete its clinical collaboration with a Japanese partner for Progenza in Japan in the near-term. The company had disclosed that it anticipated completing the collaboration before the end of 30 June but discussions have taken longer than originally anticipated.

Read Full Article

Regeneus Ltd (ASX:RGS) Grant of ASX Waiver

🕔6/28/2018 11:40:34 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced it has entered into an R&D loan facility agreement with Paddington St Finance. The maximum loan value of the facility is the lesser of $2 million or 80% of the estimated refundable tax offset credits under the ATO's R&D tax incentive.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔4/26/2018 9:05:20 AM

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly Report for the period ended 31 March, 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Trial Results of Progenza for Knee Osteoarthritis Published

🕔3/7/2018 10:55:47 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.

Read Full Article

Regeneus Ltd (ASX:RGS) 2018 Half-Year Results and Business Update

🕔2/20/2018 1:43:32 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Half-Year Report for the 6 months to 31 December 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Progenza Granted Advanced Therapy Medicinal Product Designation by European Medicines Agency

🕔2/14/2018 9:42:32 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that Progenza has been granted an Advanced Therapy Medicinal Product classification by the Committee for Advanced Therapies of the European Medicines Agency, following consultation with the European Commission.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Patent Office to Grant Patent for Cancer Vaccine Technology

🕔2/12/2018 9:48:27 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Japanese Patent Office has issued a decision to grant a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.

Read Full Article

Regeneus Ltd (ASX:RGS) Announces Successful Results in Acne Study

🕔2/6/2018 10:45:05 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that topical use of Sygenus gel for 6 weeks in adults with acne was well tolerated and showed a significant effect on the appearance of acne lesions as early as 3 weeks.

Read Full Article

Regeneus Ltd (ASX:RGS) Appoints Japan-Based Non-Executive Director with Extensive Pharmaceutical Industry Experience

🕔12/11/2017 9:59:39 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the appointment of Leo Lee as an independent non-executive director of Regeneus with effect from December.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders and CEO Presentation

🕔11/2/2017 12:58:57 PM

Regeneus Ltd (ASX:RGS) provides the Company's Chairman's address to shareholders and CEO presentation at 2017 Annual General Meeting.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation on Japan First Strategy at Ord Minnett

🕔11/1/2017 12:41:09 PM

Regeneus Ltd (ASX:RGS) provides the Company's Presentation on Japan First Strategy at Ord Minnett.

Read Full Article

Regeneus Ltd (ASX:RGS) Sygenus Shows Longer Lasting Effect on Pain than Morphine

🕔9/26/2017 9:29:00 AM

Regeneus Ltd (ASX:RGS) , a clinical-stage regenerative medicine company, today announced that a preclinical post-operative pain study has shown that topical application of Sygenus, has significantly greater and longer lasting analgesic effect than an injection of morphine.

Read Full Article

Regeneus Ltd (ASX:RGS) Edison Investment Report Issued

🕔9/11/2017 7:52:04 AM

The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.6m

🕔8/29/2017 11:29:46 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2017.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) Interview with John Martin on Progenza and the Platform Technology

🕔8/25/2017 10:15:41 AM

Regeneus Ltd (ASX:RGS) CEO John Martin talks on the release of the financial results following the company's significant progress with Japanese partner Asahi Glass Ltd (AGC) (TYO:5201)

Read Full Article

Regeneus Ltd (ASX:RGS) FY17 Results Announcement

🕔8/22/2017 9:57:16 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today released its Full-Year Report for the 12 months ending 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔7/26/2017 9:30:49 AM

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) US Patent Allowed for Sygenus Secretions Technology for Acne

🕔7/10/2017 9:26:34 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the United States Patent Office has issued a notice of allowance for a patent covering the composition, manufacture and use of the secretion stem cell technology platform, known as Sygenus, to treat acne. We recently informed the market of the new name for the secretions platform in our Q2 2017 Update.

Read Full Article

Regeneus Ltd (ASX:RGS) Q2 2017 Update

🕔7/5/2017 10:34:22 AM

Regeneus Ltd (ASX:RGS) provides the Company's latest newsletter for the quarter ended 30 June 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) to Receive Milestone Payment for Successful Phase I

🕔6/21/2017 9:10:44 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it will receive a milestone payment of US$1m from AGC for meeting the primary endpoints of its Phase 1 safety trial of Progenza in patients with knee osteoarthritis. The company reported on the positive results of the trial on 22 May 2017.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation to ChinaBio Partnering Forum

🕔5/31/2017 8:26:23 AM

Regeneus Ltd (ASX:RGS) is pleased to provide the Company's latest presentation to ChinaBio Partnering Forum.

Read Full Article

Regeneus Ltd (ASX:RGS) Japanese Patent Office to Grant Key Patent for Progenza

🕔5/24/2017 9:20:35 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Japanese Patent Office has issued a decision to grant a key patent covering the composition, manufacture and use of Progenza stem cell technology.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Trial Results for Progenza

🕔5/22/2017 9:52:04 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis, meeting the primary endpoint of safety and tolerability.

Read Full Article

FINANCE VIDEO: Regeneus Ltd (ASX:RGS) CEO John Martin Talks about the Licensing of Progenza in Japan

🕔3/9/2017 9:00:20 AM

With the recent announcement of a significant licensing deal with AGC Ltd in Japan, the company is set to build on their platform for the delivery of Progenza to deal with many healthcare issues from arthritis and pain, to genetic disorders.

Read Full Article

Regeneus Ltd (ASX:RGS) Enters Into Collaborative Agreement With Asahi Glass (TYO:5201) To Commercialize Progenza

🕔1/13/2017 2:19:42 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced that it has entered into a strategic collaboration and licensing agreement with AGC Asahi Glass (AGC) (TYO:5201), a world-leading manufacturer of glass, chemicals, high-tech materials and biopharmaceuticals.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Presentation

🕔8/24/2016 9:59:03 AM

Regeneus Ltd (ASX:RGS) are pleased to provide a Company Presentation for the Full Year Results for FY16.

Read Full Article

Regeneus Ltd (ASX:RGS) FY16 Results Announcement

🕔8/24/2016 9:48:39 AM

Regeneus Ltd (ASX:RGS today reported its 2016 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cell-based therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4E and Annual Report 2016

🕔8/24/2016 9:34:59 AM

Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent to Grant on Stem Cell Secretions Technology for Acne

🕔8/1/2016 10:33:03 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the European Patent Office has decided to grant a patent covering the use of the company's stem cell secretions technology for the topical treatment of acne.

Read Full Article

Regeneus Ltd (ASX:RGS) Q2 2016 Update

🕔7/1/2016 1:30:06 PM

In late May, members of the executive team visited Japan to advance discussions with potential manufacturing and commercial partners for Progenza in Japan. We are pleased to report our meetings went well and we are on track to enter into our first significant partnering agreement in Japan by the end of September 2016.

Read Full Article

Regeneus Ltd (ASX:RGS) Potential Japan Licence Deal a STEP Closer

🕔5/20/2016 11:18:35 AM

Regeneus Ltd (ASX:RGS) announce that an investment report by Edison titled "Potential Japan licence deal a STEP closer" has been published on the Regeneus website.

Read Full Article

Regeneus Ltd (ASX:RGS) Australian Research Council Linkage Grant to Progress Stem Cell Research into Treating Chronic Pain

🕔5/17/2016 9:14:11 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced the Australian Research Council (ARC) had awarded a Linkage Grant of $340,000 to a research consortium that includes Regeneus collaborating with leading researchers from Macquarie University and the University of Adelaide.

Read Full Article

Regeneus Ltd (ASX:RGS) Enrolment Complete and Positive Safety in Progenza Trial For Osteoarthritis

🕔5/16/2016 9:23:45 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of enrolment of all 20 patients in the STEP trial. Further, a review of the cumulative study safety data by the study safety oversight committee identified no safety concerns.

Read Full Article

The Life Sciences Report: Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

🕔5/15/2016 10:23:22 AM

The Life Sciences Report: Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4C - Quarterly

🕔4/28/2016 9:22:33 AM

Regeneus Ltd (ASX:RGS) Achieved better than targeted net operating cash flow for the quarter. Cash outflow for the quarter was $1.44 million. Cash flow is tracking consistently better than the target of $1.70 million per quarter.

Read Full Article

Regeneus Ltd (ASX:RGS) Half Year Results Announcement

🕔2/29/2016 9:26:29 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported financial results and operational highlights for the 6 month period ended 31 December 2015.

Read Full Article

Regeneus Ltd (ASX:RGS) Appendix 4D and Half Yearly Report

🕔2/29/2016 9:25:59 AM

Regeneus Ltd (ASX:RGS) is an ASX-listed clinical-stage regenerative medicine company developing cell-based therapies to treat unmet medical needs with a focus on osteoarthritis and other musculoskeletal disorders and oncology diseases for both humans and animals.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Safety of First Cohort in Progenza Stem Cell Trial

🕔1/12/2016 9:14:12 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of a review of safety from the first cohort of 10 patients in the STEP trial.

Read Full Article

Regeneus Ltd (ASX:RGS) Patent Granted for Cancer Vaccine Technology

🕔12/15/2015 9:42:48 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine technology company, today announced that the Australian Patent Office has granted a patent covering the use of cancer vaccine technology for the treatment of a range of cancers in humans and animals.

Read Full Article

Regeneus Ltd (ASX:RGS) To Present at Austrade Mission on Regenmed in Japan

🕔12/7/2015 9:03:44 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced today that John Martin, CEO, will present at Austrade's Mission on Regenerative Medicine Opportunities in Japan, on Monday 7 December in Tokyo and Wednesday 9 December in Kobe.

Read Full Article

Asian Equities Report: November 26 2015 - Regeneus Ltd (ASX:RGS) Commences Canine Cancer Vaccine Trial

🕔11/26/2015 10:13:55 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today the commencement of a trial of its cancer vaccine technology, Kvax, in combination with chemotherapy as a treatment for canine lymphoma.

Read Full Article

Regeneus Ltd (ASX:RGS) Canine Cancer Vaccine Trial on Lymphoma at SASH Commenced

🕔11/26/2015 9:26:36 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today the commencement of a trial of its cancer vaccine technology, Kvax, in combination with chemotherapy as a treatment for canine lymphoma.

Read Full Article

Regeneus Ltd (ASX:RGS) High Potency Stem Cells for Next Generation Cell Therapies

🕔11/24/2015 9:06:48 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that it has secured exclusive rights to commercialise a breakthrough cell identification and selection technology that for the first time in the world allows high potency secreting stem cells to be identified and selected for the manufacture of next generation cell therapies.

Read Full Article

Regeneus Ltd (ASX:RGS) Patent Granted for Allogeneic Stem Cell Technology Platform

🕔11/11/2015 9:39:27 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the Australian Patent Office has granted a key patent covering the use of the company's allogeneic "off-the-shelf" stem cell technology for the treatment of osteoarthritis and other inflammatory conditions for human and animal applications.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address and CEO Presentation To Shareholders

🕔11/9/2015 3:10:52 PM

We are pleased to report that FY15 has been a productive and positive year for Regeneus Ltd (ASX:RGS). We have achieved a number of significant research and development, clinical and business milestones that have put the company in a good position to unlock value in our regenerative medicine technology and clinical assets in FY16 and beyond.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive Clinical Results for CryoShot Equine

🕔11/5/2015 9:26:32 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, announced today interim trial results showing that its allogeneic "off-the-shelf" stem cell therapy, CryoShot, has positive results on early orthopaedic developmental disease in Yearling Thoroughbreds and compares favourably against the use of conventional therapies like corticosteroids.

Read Full Article

Regeneus Ltd (ASX:RGS) Partners with a Leading Animal Health Company

🕔11/2/2015 9:10:05 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, announced today that it had entered into an agreement with one of the world's top 5 animal health companies to partner the development and commercialisation of CryoShot Canine.

Read Full Article

Regeneus Ltd (ASX:RGS) First Patient Safely Treated in Cancer Vaccine Trial

🕔10/27/2015 9:59:25 AM

Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the first patient has been enrolled and safely treated in the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2015 to Shareholders

🕔10/19/2015 10:16:33 AM

Regeneus Ltd (ASX:RGS) are pleased to provide the Company's Annual Report for 2015 to shareholders.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive Refund of $3.4 Million

🕔10/13/2015 10:01:17 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $3.4m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2015 financial year.

Read Full Article

Regeneus Ltd (ASX:RGS) FY15 Full-Year Results and Business Update

🕔8/31/2015 6:18:14 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported its 2015 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cellbased therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.

Read Full Article

Regeneus Ltd (ASX:RGS) First Patient Treated in Progenza Stem Cell Trial for Knee Osteoarthritis

🕔8/10/2015 9:56:49 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the first patient has been enrolled and treated in the STEP (Safety, Tolerability and Efficacy of Progenza) trial, the first clinical trial of Progenza, the company's allogeneic stem cell product for the treatment of knee osteoarthritis.

Read Full Article

Regeneus Ltd (ASX:RGS) Approval For Personalised Cancer Immunotherapy Trial

🕔5/25/2015 8:27:42 AM

Regeneus (ASX:RGS), a clinical stage regenerative medicine company, has received ethics approval to commence its first-in-human trial for a personalised therapeutic cancer vaccine that is aimed at harnessing the body's own immune system to fight cancer cells.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives Approval for Progenza OA Trial

🕔4/22/2015 10:05:35 AM

Regeneus (ASX:RGS), a clinical stage regenerative medicine company focused on the development of cell therapies, announced today that it has received ethics approval for a clinical trial of its new off-the-shelf allogeneic stem cell treatment, known as Progenza, for patients with knee osteoarthritis.

Read Full Article

Regeneus (ASX:RGS) CEO John Martin's Presentation at the Alliance of Regenerative Medicine (ARM) Investor Day 2015

🕔4/14/2015 12:30:15 PM

Organised by the Alliance for Regenerative Medicine (ARM), the 3rd Annual Regenerative Medicine Investor Day was held on March 25th 2015 in New York City.

Read Full Article

Regeneus Ltd (ASX:RGS) Achievement of key stem cell manufacturing milestone

🕔4/7/2015 9:44:34 AM

Regeneus (ASX:RGS) announced today that it has achieved a key manufacturing milestone for its proprietary "off-the-shelf" allogeneic stem cell therapy product, Progenza.

Read Full Article

Regeneus Ltd (ASX:RGS) To Present at Regenerative Medicine Investor Day in New York

🕔3/23/2015 8:45:13 AM

Regeneus Ltd (ASX:RGS) announced today that John Martin, CEO, will present at the 3rd Annual Regenerative Medicine Investor Day to be held Wednesday, March 25, 2015 in New York City.

Read Full Article

Regeneus Ltd (ASX:RGS) Positive preclinical results for Progenza

🕔3/9/2015 10:07:04 AM

Regenerative medicine company, Regeneus (ASX:RGS) announced today that it has successfully completed a preclinical study to support its first-in-human safety study of Progenza, its allogeneic, off-theshelf stem cell product for osteoarthritis (OA).

Read Full Article

New Director joins Regeneus Ltd (ASX:RGS) Board of Directors

🕔2/25/2015 11:32:54 AM

Regenerative medicine company, Regeneus Ltd (ASX:RGS) is pleased to announce the appointment of Dr Glen Richards as an independent non-executive director of Regeneus with effect from April.

Read Full Article

Regeneus Ltd (ASX:RGS) Regeneus Half-Year Announcement

🕔2/19/2015 2:22:11 PM

Regenerative medicine company, Regeneus Ltd (ASX:RGS), today reported its financial results for the half-year ended 31 December 2014.

Read Full Article

Regeneus Ltd (ASX:RGS) Regeneus Half-Yearly Report and Accounts

🕔2/19/2015 2:20:43 PM

Regeneus Ltd (ASX:RGS) Regeneus Half-Yearly Appendix 4D and Accounts. Following is the review of operations for the period.

Read Full Article

Regeneus Ltd (ASX:RGS) Patent Granted For Protecting Cryopreserved Stem Cells

🕔12/19/2014 9:44:10 AM

Regenerative medicine company, Regeneus Ltd (ASX:RGS), announced today the granting by the Australian Patent Office of Australian patent number 2013203072. This Regeneus owned patent covers a method for freezing cells that maintains viability and functionality of the cells.

Read Full Article

Regeneus Ltd (ASX:RGS) New Japanese Laws to Fast Track Cell Therapy Take Effect

🕔11/26/2014 10:07:06 AM

Regeneus Ltd (ASX:RGS) announces that the new Japanese regenerative medicine laws that passed through Parliament in November 2013, have come into effect. These new laws reform the pharmaceutical and medical regulations related to regenerative medicine and provide a rapid approval process specifically designed for regenerative medicine products.

Read Full Article

Regeneus Ltd (ASX:RGS) Concludes Strategic Review and Sets Platform For Next Phase of Development

🕔11/24/2014 9:00:39 AM

Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces that it has completed a strategic review of the business resulting in the company taking a number of measures to streamline its management structure, operations and reduce costs.

Read Full Article

Regeneus Ltd (ASX:RGS) Acne Treatment Patent Granted

🕔11/14/2014 9:23:57 AM

Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces today the granting by the Australian Patent Office of Australian patent number 2013203164. This Regeneus owned patent, Therapeutics for skin conditions, provides protection for the company's stem cell secretions technology for the topical treatment of acne.

Read Full Article

Regeneus Ltd (ASX:RGS) Board and Management Changes To Increase Commercial Partnerships

🕔11/10/2014 1:36:11 PM

Regenerative medicine company, Regeneus Ltd (ASX:RGS), announces changes to its Board and senior management team consistent with its focus on increasing commercial and partnering activities for its regenerative medicine products, reducing costs and greater Board independence.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation to Shareholders at AGM 2014

🕔10/28/2014 2:01:42 PM

Regeneus Ltd (ASX:RGS) Presentation to Shareholders at AGM 2014 with significant achievements to date including the successful translation of 4 regenerative medicine technology platforms into products for musculoskeletal and oncology applications for humans and animals.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders

🕔10/28/2014 1:55:18 PM

Together with the company's committed and capable management and staff, the Board is intent on realising Regeneus' full potential, not only to deliver significant benefits to both human and animal health but also to justify shareholders' faith in Regeneus through enhancing the value of your investment in the company.

Read Full Article

Regeneus Ltd (ASX:RGS) Response to 7.30 Media Commentary

🕔10/9/2014 9:54:08 AM

Regenerative medicine company Regeneus Ltd (ASX:RGS) wishes to officially respond to the ABC 7.30's Sell Therapy story, which aired on 6th October 2014.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive Refund of $3.7m

🕔9/25/2014 11:20:28 AM

Regeneus Ltd (ASX:RGS) is pleased to announce it has received $3.7m from the Australian Government's Research and Development Tax Incentive Program for activities conducted during the 2014 financial year.

Read Full Article

Regeneus Ltd (ASX:RGS) HiQCell Regenerative Medicine Clinic to open in Singapore

🕔9/23/2014 9:40:01 AM

Regenerative medicine company, Regeneus Ltd (ASX:RGS), today announced plans to open the HiQCell Regenerative Medicine Clinic in Singapore, and the appointment of leading specialist sports physician, Dr Patrick Goh, as Medical Director.

Read Full Article

Regeneus Ltd (ASX:RGS) Kvax Cancer Vaccine Available in Australia, US Trial Begins

🕔9/11/2014 9:40:38 AM

Regenerative medicine company, Regeneus (ASX:RGS) today announced that it had officially launched its Kvax canine cancer treatment within the Australian veterinary market.

Read Full Article

Regeneus Ltd (ASX:RGS) Share Purchase Plan Closes Oversubscribed

🕔9/9/2014 10:16:35 AM

Regeneus Ltd (ASX:RGS) is pleased to announce that it has successfully achieved its target of raising A$3m through its Share Purchase Plan offered to shareholders. This now completes the second part of the company's A$6m raising announced to the market on 8 August 2014.

Read Full Article

AFL approves use of Regeneus Ltd's (ASX:RGS) Stem Cell Therapy, HiQCell(R) for Injured Players

🕔8/27/2014 11:56:06 AM

Regeneus Ltd (ASX:RGS) announced today that the Australian Football League (AFL) has granted caseby-case approval for the use of its innovative stem cell therapy, HiQCell(R) as a treatment option for injured AFL players, typically including impact related osteoarthritis and tendonitis.

Read Full Article

News

Regeneus Ltd (ASX:RGS) Quarterly Report

🕔1/30/2019 3:51:34 PM

Regeneus Ltd (ASX:RGS) provides the Company's Quarterly results for the period ended 31 December 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) New CEO Appointed to Accelerate Global Growth

🕔1/23/2019 9:48:46 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.

Read Full Article

Regeneus Ltd (ASX:RGS) Chinese Patent Granted for Biomarkers for Stem Cell Therapy

🕔12/3/2018 9:34:26 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.

Read Full Article

Regeneus Ltd (ASX:RGS) Chairman's Address to Shareholders

🕔11/22/2018 2:06:22 PM

Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.

Read Full Article

Regeneus Ltd (ASX:RGS) Presentation for AusBiotech 2018

🕔10/31/2018 4:26:22 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.

Read Full Article

Regeneus Ltd (ASX:RGS) Quarterly Results for the Period Ended 30 September 2018

🕔10/24/2018 9:08:53 AM

Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) European Patent Office Issues Notice of Intention to Grant European Patent

🕔10/18/2018 9:11:57 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.

Read Full Article

Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

🕔9/6/2018 9:18:09 AM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

🕔8/30/2018 2:32:07 PM

Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.

Read Full Article

Regeneus Ltd (ASX:RGS) Annual Report 2018

🕔8/30/2018 2:13:22 PM

Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.

Read Full Article
###

105,926 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 195) (Last 30 Days: 1625) (Since Published: 48536) 

Markets ASX:RGS

Company Data

    Headquarters
  • Ground floor, 25 Bridge Street
    Pymble NSW 2073
    Australia
  • Telephone
  • +61-2-9499-8010 
  • Fax
  • +61-2-9499-8020 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.regeneus.com.au
  • E:
  • info@regeneus.com.au

Presentations

Research Report

Quarterly Report

Social Media